Correspondence 0001104659-24-094587 from CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738) (CASIF)

CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)
Date: Aug. 29, 2024 · CIK: 0001962738 · Accession: 0001104659-24-094587

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-281621

Date

August 29, 2024

Author

Form

CORRESP

Company

CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)

Letter

VIA EDGAR Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission Re: CASI Pharmaceuticals, Inc. Registration Statement on Form F-3 Filed on August 16, 2024 File No. 333-281621

Dear Mr. Howes:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), CASI Pharmaceuticals, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form F-3 (File No. 333-281621) be accelerated by the Securities and Exchange Commission to 4:00 p.m., Washington D.C. time on Tuesday, September 3, 2024, or as soon thereafter as may be practicable.

In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Please contact Rui Zhang, at 617-945-6381 or ruiz@casipharmaceuticals.com if you have any questions. Thank you very much.

[Signature page follows]

Sincerely,
CASI Pharmaceuticals, Inc.

Show Raw Text

CORRESP
1
filename1.htm

CASI PHARMACEUTICALS, INC.

1701-1702, China Central Office Tower 1

No. 81 Jianguo Road Chaoyang District

Beijing, 100025

People’s Republic of China

August 29, 2024

VIA EDGAR

Mr. Tyler Howes

Division of Corporation Finance

Office of Life Sciences

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

    Re:
    CASI Pharmaceuticals, Inc.

Registration Statement on Form F-3

Filed on August 16, 2024

File No. 333-281621

Dear Mr.
Howes:

Pursuant to Rule 461 under the Securities Act of
1933, as amended (the “Act”), CASI Pharmaceuticals, Inc. (the “Company”) hereby requests that the effective date
of the Company’s Registration Statement on Form F-3 (File No. 333-281621) be accelerated by the Securities and Exchange Commission
to 4:00 p.m., Washington D.C. time on Tuesday, September 3, 2024, or as soon thereafter as may be practicable.

In making this acceleration request, the Company
acknowledges that it is aware of its responsibilities under the Act.

Please contact Rui Zhang, at 617-945-6381 or ruiz@casipharmaceuticals.com
if you have any questions. Thank you very much.

[Signature page follows]

    Sincerely,

    CASI Pharmaceuticals, Inc.

    By:
    /s/ Wei-Wu He

    Name:
    Wei-Wu He

    Title:
    Chief Executive Officer and Chairman of the Board of Directors

    2

SecProbe.io